Biological and molecular characterization of PNH-like lymphocytes emerging after Campath-1H therapy

British Journal of Haematology

Volumn 112, Issue 4, 2001, Pages 969-971

  Fracchiolla, Nicola S ^a   Barcellini, Wilma ^a   Bianchi, Paola ^a   Motta, Marina ^a   Fermo, Elisa ^a   Cortelezzi, Agostino ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Campath 1H; CLL; Cytokines; PIG A; PNH like lymphocytes

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHENOTYPE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CASE-CONTROL STUDIES; FLOW CYTOMETRY; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-6; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHYTOHEMAGGLUTININS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035053076     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02677.x     Document Type: Article

References (9)

1. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment
2. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma
3. Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia
4. Diminished production of interleukin-6 in chronic lymphocytic leukaemia (B-CLL) cells from patients at advanced stages of disease
5. Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoletic precursors and interleukin-6 production
6. High incidence of transiently appearing complement-sensitive bone marrow precursor cells in patients with severe aplastic anemia. A possible role of high endogenous interleukin (IL) -2 in their suppression
7. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells
8. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment
9. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism